Better Buy: Inovio Pharmaceuticals vs. Novavax
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful. That group includes Novavax (NASDAQ: NVAX) and Inovio Pharmaceuticals (NASDAQ: INO). The former did launch a coronavirus vaccine in the U.S., but the latter never got that far.
Both have substantially lagged the market over the past three years, but they now seem to be experiencing significant rebounds; shares of Novavax and Inovio have soared since 2024 started. Which of these two biotechs can outperform the other moving forward? Let's take a look.
Source Fool.com
Novavax Inc. Stock
€12.28
-4.310%
Our community is currently high on Novavax Inc. with 5 Buy predictions and 1 Sell predictions.
With a target price of 17 € there is a positive potential of 38.44% for Novavax Inc. compared to the current price of 12.28 €.
